Media coverage about Kadmon (NYSE:KDMN) has trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Kadmon earned a media sentiment score of 0.22 on Accern’s scale. Accern also gave news articles about the company an impact score of 45.5812130350058 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the news articles that may have effected Accern’s analysis:
A number of research firms recently commented on KDMN. Zacks Investment Research downgraded shares of Kadmon from a “buy” rating to a “hold” rating in a research report on Tuesday, January 16th. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 target price on shares of Kadmon in a research report on Friday, December 15th. Finally, WBB Securities downgraded shares of Kadmon from a “hold” rating to a “sell” rating and set a $3.00 target price on the stock. in a research report on Monday, October 9th. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and two have assigned a buy rating to the stock. Kadmon presently has a consensus rating of “Hold” and an average target price of $8.65.
Shares of Kadmon (NYSE KDMN) traded down $0.07 during trading on Friday, reaching $5.14. 729,273 shares of the company’s stock traded hands, compared to its average volume of 1,409,062. The stock has a market cap of $404.23, a P/E ratio of -2.94 and a beta of 5.39. Kadmon has a 52 week low of $2.05 and a 52 week high of $5.86.
Kadmon (NYSE:KDMN) last announced its quarterly earnings data on Thursday, November 9th. The company reported ($0.42) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.38) by ($0.04). The company had revenue of $2.28 million for the quarter, compared to analysts’ expectations of $5.69 million. During the same period last year, the business earned ($4.24) EPS. The firm’s revenue for the quarter was down 60.0% on a year-over-year basis. analysts expect that Kadmon will post -1.62 EPS for the current year.
WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Kadmon (KDMN) Share Price” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another website, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/04/kadmon-kdmn-earns-daily-coverage-optimism-rating-of-0-22.html.
Kadmon Company Profile
Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.